Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.45 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24660470 | 0.93 | KCNT1 (0.61) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660775 | 0.93 | KCNT1 (0.61) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660613 | 0.93 | KCNT1 (0.61) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL25601543 | 0.88 | KCNT1 (0.51) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660827 | 0.87 | ACACB (0.51) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660721 | 0.85 | KCNT1 (0.59) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL22637519 | 0.85 | KCNT1 (0.59) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660575 | 0.85 | KCNT1 (0.59) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660174 | 0.85 | KCNT1 (0.48) | KCNT1PPARDPPARAKCNQ1KCNH2 | |
| SCHEMBL24660475 | 0.85 | KCNT1 (0.49) | KCNT1PPARDPPARAKCNQ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109692-A1 | KCNT1 INHIBITORS AND METHODS OF USE | UCB Biopharma SRL (BE) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109692-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNJ2, KCNT2 | KCNT1 1/4885PPARD 3460/4885PPARA 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.